The majority of patients with Non-Small Cell Lung Cancer (NSCLC) are diagnosed with advanced disease (Stage IV). The site of the metastasis as well as the underlying disease influences the outcome and the patient's quality of life. objeCtives: To evaluate the impact of brain metastases compared with other metastatic sites on health-related quality of life (EQ-5D) and physician-perceived life expectancy in stage IV NSCLC patients. Methods: Data were drawn from the Adelphi NSCLC Disease-Specific Programme (DSP ® ), a cross-sectional survey of 120 pulmonologists and oncologists and their NSCLC patients conducted between July and September 2010 in France and Germany. Each physician completed detailed record forms on 10 advanced patients being actively treated for NSCLC. Patients were invited to complete an equivalent patient self-completion questionnaire (PSC) which included the EQ-5D. Analysis was conducted on patients with only one metastatic site, either brain, contralateral lung, adrenal gland, bone or liver. Mann-Whitney tests were used to assess the differences between metastatic sites. Results: 498 patients with one metastatic site were identified of whom 325 (65%) completed a PSC. The higher the EQ-5D score the better the health state, EQ-5D was significantly lower for patients with brain metastases (mean 0.52, n= 29) compared with contralateral lung metastases (0.69, n= 111, p= 0.0196); adrenal glands (0.83, n= 43, p= 0.0001) and liver (0.71, n= 46, p= 0.0191). No significant difference was observed between brain and bone metastases (0.53, n= 92, p= 0.8219). Estimated life expectancy was significantly shorter for brain metastases (25.3 weeks) compared with contralateral lung (50.5 weeks), bone (49.4 weeks), adrenal glands (48.7 weeks) and liver (44.9 weeks) (all p< 0.01). ConClusions: The development of brain metastases in patients with advanced NSCLC is associated with a significant reduction in quality of life and estimated life expectancy compared with other metastatic sites. objeCtives: Men with mCRPC are at risk of experiencing SREs, defined as pathologic bone fracture ("fracture"), spinal cord compression ("compression"), and the need for radiotherapy or surgery to bone ("radiotherapy/surgery"). We examined the patient and clinical relevance of SREs for HRQoL in men with mCRPC. Methods: We analysed data from patients experiencing any type of SRE (n= 587; irrespective of treatment) in PREVAIL -a phase 3 trial of enzalutamide (n= 872) vs. placebo (n= 845) in asymptomatic/mildly symptomatic chemo-naïve mCRPC patients. For patients with multiple SREs, only the first event was included. HRQoL was assessed using the FACT-P and EQ-5D tools. Impact of first SRE on HRQoL was evaluated as follows: especially in comparative and longitudinal studies is recommended in order to enhance use of BQ in clinical decision making around BR modalities.
PCN201 PatieNts' Priorities iN tHe treatmeNt of NeuroeNdoCriNe tumors: aN aNalytiC HierarCHy ProCess
Mühlbacher A. C. , Juhnke C. , Kaczynski A. Hochschule Neubrandenburg, Neubrandenburg, Germany objeCtives: Neuroendocrine tumors (NET) are relatively rare, usually slow-growing malignant tumors. So far there is no data on the patient preferences/priorities regarding the therapy of NET. This empirical study aimed at the elicitation of patient priorities in the drug treatment of NET. Methods: Qualitative patient interviews (N= 9) were conducted. To elicit patient's perspective regarding various treatment aspects of NET a self-administered questionnaire using Analytic Hierarchy Process (AHP) was developed. The data collection was carried out using paper questionnaires supported by an item response system in a group discussion. To evaluate the patient-relevant outcomes, the eigenvector method was applied. Results: N= 24 patients, experts and relatives participated in the AHP survey. In the AHP all respondents had clear priorities for all considered attributes. The attribute "overall survival" was the most significant feature of a drug therapy for all respondents. As in the qualitative interviews, "efficacy attributes" dominated the side effects in the AHP as well. The evaluation of all participants thus showed the attributes "overall survival" (Wglobal: 0.418), "progression free survival" (Wglobal: 0.172) and "response to treatment" (Wglobal: 0.161) to be most relevant. "Occurrence of abdominal pain" (Wglobal: 0.051) was ranked last, with "tiredness/fatigue" and "risk of a hypoglycemia" (Wglobal: 0.034) on a shared seventh place. ConClusions: The results thus provide evidence about how much influence a treatment capacity has on therapeutic decision. Using the AHP major aspects of drug therapy from the perspective of those affected were captured, and positive and negative therapeutic properties could be related against each other. Based on the assessment of the patient's perspective further investigation must elicit patient preferences for NET drug therapy. In the context of a discrete choice experiment or another choice -based method of preference measurement, the results obtained here can be validated and the therapeutic features weighted according to their preferability. objeCtives: Despite the availability of a wide number of treatments for relapsed/ refractory (r/r) chronic lymphocytic leukemia (CLL) and r/r mantle cell lymphoma (MCL), no standard of care has emerged. There are no studies evaluating preferences for treatment outcomes for r/r CLL and r/r MCL. This study was designed to elicit preferences for r/r MCL and r/r CLL treatment outcomes among patients, the general public and physicians experienced in treating CLL/MCL in Germany. Methods: Interviews (90 minutes) in German of 6 CLL/6 MCL hematologists, 6 r/r CLL and 5 r/r MCL patients were conducted (total 23 interviews). Participants were asked to state their most important treatment outcomes. Transcripts were translated to English and analyzed by counting the number of times each outcome was mentioned. We present here results of patient and physician preferences. Results: r/r CLL patients mention overall survival (OS; 5 counts), mode of treatment administration (4), quality of life (QOL) aspects (4) and progression free survival (PFS) disease control (4). A tolerable side effect (SE) profile/controlling disease symptoms was mentioned by 3 patients. Other treatment outcomes were infections, nausea (2 each), fatigue, weight loss, pain, fever, polyneuropathy and long treatment intervals (1 each). CLL physicians mentioned OS (4), QOL (4) and PFS (4). r/r MCL patients mentioned efficacy benefits such as cure (4) and OS (2), PFS (1); various QOL aspects (5) and a tolerable SE profile/controlling disease (3). Other treatment outcomes were longterm organ damage (2), hair loss, nausea and night sweat (1 each). MCL physicians mentioned OS (6), QOL (5) and a tolerable SE profile (4). ConClusions: Extending life, disease control, maintaining QOL and avoiding SE are important r/r MCL/CLL treatment outcomes to German patients and physicians. Neubrandenburg, Neubrandenburg, Germany objeCtives: Lung cancer is a major cause of cancer-related deaths and thus represents a global health problem. To date, decisions on which treatment to use are often driven by health care professionals' opinions. The perspective of patients with metastatic non-small cell lung cancer (NSCLC) on the importance of different treatment criteria and the ranking of these decision criteria are rarely taken into consideration. Aim of the study is the evaluation of patients' preferences for different treatment characteristics of NSCLC patients. Methods: The literature review and 10 qualitative interviews revealed seven patient-relevant treatment attributes. A Discrete-Choice Experiment (DCE) was used to rank the patient-relevant treatment characteristics. The DCE was conducted using a fractional factorial design (Ngene) and the statistical data analysis used random effect logit and GLLAMM latent class models for subgroup identification. Results: In total N= 211 patients with metastatic NSCLC participated in the computer-assisted personal interviews. The estimation revealed a clear dominance for "progression-free survival" (coef.: 1.087) and "tumor-associated symptoms (cough, shortness of breath and pain)" (coef.: 1.090), followed by the side effects: "nausea and vomiting" (coef.: 0.605), "rash" (coef.: 0.432), "diarrhea" (coef.: 0.427) and "tiredness and fatigue" (coef.: 0.423). The "mode
PCN202 wHat relaPsed/refraCtory Cll/mCl treatmeNt outComes do germaN PatieNts aNd PHysiCiaNs fiNd most imPortaNt? results from Qualitative iNterviews

